These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 6375610)

  • 21. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):615-8. PubMed ID: 1587076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical observations on the treatment of obese patients with dexfenfluramine].
    Cairella M; Pisculli M; Petraroli AR; Riganelli S; Saracino A; Siani V
    Clin Ter; 1990 Jun; 133(5):289-97. PubMed ID: 2143712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
    Weintraub M
    Clin Pharmacol Ther; 1992 May; 51(5):581-5. PubMed ID: 1445528
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term treatment with fenfluramine in obese subjects.
    Sensi S; Della Loggia F; Del Ponte A; Guagnano MT
    Int J Clin Pharmacol Res; 1985; 5(4):247-53. PubMed ID: 4055167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenfluramine and phentermine.
    Howlin D
    Ann Intern Med; 2001 Nov; 135(9):840-1. PubMed ID: 11694113
    [No Abstract]   [Full Text] [Related]  

  • 28. Bitter pills, bad medicine.
    Golden F
    Time; 2001 Jun; 157(22):76. PubMed ID: 11432381
    [No Abstract]   [Full Text] [Related]  

  • 29. Anesthetic considerations for the new antiobesity medications.
    Jeffers LA
    AANA J; 1996 Dec; 64(6):541-4. PubMed ID: 9204789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended-release fenfluramine: patient acceptance and efficacy of evening dosing.
    Weintraub M; Sriwatanakul K; Sundaresan PR; Weis OF; Dorn M
    Clin Pharmacol Ther; 1983 May; 33(5):621-7. PubMed ID: 6340909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term weight control study. VI. Individual participant response patterns.
    Weintraub M; Sundaresan PR; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):619-33. PubMed ID: 1587077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bipolar depression associated with fenfluramine and phentermine.
    Zimmer JE; Gregory RJ
    J Clin Psychiatry; 1998 Jul; 59(7):383-4. PubMed ID: 9714271
    [No Abstract]   [Full Text] [Related]  

  • 33. Anorectic effectiveness of differing dosage forms of fenfluramine.
    Tisdale SA; Ervin DK
    Curr Ther Res Clin Exp; 1976 Jun; 19(6):589-94. PubMed ID: 819218
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control.
    Preuss HG; Garis RI; Bramble JD; Bagchi D; Bagchi M; Rao CV; Satyanarayana S
    Int J Clin Pharmacol Res; 2005; 25(3):133-44. PubMed ID: 16366421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacologic management of obesity.
    Cerda JJ
    J Fla Med Assoc; 1997 Feb; 84(2):89-92. PubMed ID: 9066231
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study.
    Enzi G; Crepaldi G; Inelmen EM; Bruni R; Baggio B
    Clin Neuropharmacol; 1988; 11 Suppl 1():S173-8. PubMed ID: 3052815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
    Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
    Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet alpha-adrenergic receptors in obesity: alteration with weight loss.
    Sundaresan PR; Weintraub M; Hershey LA; Kroening BH; Hasday JD; Banerjee SP
    Clin Pharmacol Ther; 1983 Jun; 33(6):776-85. PubMed ID: 6303674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current status of antiobesity drugs.
    Galloway SM; Farquhar DL; Munro JF
    Postgrad Med J; 1984; 60 Suppl 3():19-26. PubMed ID: 6393107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a combined behavioral and pharmacological program on weight loss.
    Brightwell DR; Naylor CS
    Int J Obes; 1979; 3(2):141-8. PubMed ID: 528125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.